Eight months after receiving approval for Erbitux in colorectal cancer, ImClone Systems Inc. and Bristol-Myers Squibb Co. set out on another Phase III program for the drug, this time targeting non-small-cell lung cancer. (BioWorld Today)
As it prepares regulatory filings for anidulafungin and dalbavancin, Vicuron Pharmaceuticals Inc. priced a public offering worth $70.8 million in gross proceeds. (BioWorld Today)
